Logo Logo
Help
Contact
Switch Language to German

Müller, Rüdiger B.; Späth, Michael; Restorff, Cord von; Ackermann, Christoph; Schulze-Koops, Hendrik and Kempis, Johannes von (2019): Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol. In: Journal of Clinical Medicine, Vol. 8, No. 3, 302

Full text not available from 'Open Access LMU'.

Abstract

Background: Treatment of rheumatoid arthritis (RA) includes the use of conventional (cs), biologic (b) disease-modifying anti-rheumatic drugs (DMARDs) and oral, intramuscularly, intravenous, or intraarticular (IA) glucocorticoids (GCs). In this paper, we analysed whether a treat-to-target (T2T) strategy optimizing csDMARD, oral, and IA-GC treatment as an adjunct new therapy to a new certolizumab pegol (CZP) therapy improves the effectivity in RA patients. Methods: 43 patients with active RA (>= 6 tender, >= 6 swollen joints, ESR >= 20 mm/h or CRP >= 7mg/L) despite csDMARD treatment for >= 3 months and naive to bDMARDs were randomized to CZP (200 mg/2 weeks after loading with 400 mg at weeks 0-2-4) plus a treat-to-target strategy (T2T, n = 21), or to CZP added to the established csDMARD therapy (fixed regimen, n = 22). The T2T strategy consisted of changing the baseline csDMARD therapy (1) SC-methotrexate (dose: 15 >= 20 >= 25 mg/week, depending on the initial dose) >= leflunomide (20 mg/d) >= sulphasalazine (2 x 1000 mg/d) plus (2) oral GCs (prednisolone 20-15-12.5-10-7.5-5-2.5-0 mg/d tapered every five days) and (3) injections of <= 5 affected joints with triamcinolone. DMARD modification and an addition of oral GCs were initiated, depending on the achievement of low disease activity (DAS 28 < 3.2). The primary objective was defined as the ACR 50 response at week 24. Results: ACR 50 was achieved in 76.2% of the T2T, as compared to 36.4% of the fixed regimen patients (p = 0.020). ACR 20 and 70 responses were achieved in 90.5% and 71.4% of the T2T patients and 59.1% and 27.3% of the fixed regimen patients, respectively (p = 0.045 and p = 0.010, respectively). The adverse event rate was similar for both groups (T2T n = 51;fixed regimen n = 55). Conclusion: Treat-to-target management with the optimization of csDMARDs, oral, and IA-GCs of RA patients in parallel to a newly established CZP treatment was safe and efficacious in comparison to a fixed regimen of csDMARDs background therapy.

Actions (login required)

View Item View Item